Stockreport

INmune Bio, Inc. Announces Initiation of Clinical Program Targeting Soluble TNF to Determine if the Company’s TNF Inhibitor (DN-TNF) Platform May Prevent Complications of Cytokine Storm Ca...

INmune Bio Inc. - Common stock  (INMB) 
PDF Conference call at 4:15 PM ET with management to discuss the science and strategy of clinical trial to determine if ?the Company’s DN-TNF platform could be used to treat [Read more]